THE CURIOUS CASE OF LOMITAPIDE


Shariq Naeem Syed, Vandana Roy, Piyush Misra, Akhil Dahiya

Abstract


Lomitapide is a new Microsomal transfer protein inhibitor. It has been approved as an orphan drug for treating homozygous familial hypercholetelemia. The drug went through various see-saw phases in its brief life. Understanding the life history of Lomitapide gives a unique opportunity to analyze diverse case scenarios during clinical trials and their rectification by using scientific methodology. 


| PDF |

References


Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003 Jan;44(1):22-32.

FDA approves new orphan drug for rare cholesterol disorder. FDA NEWS RELEASE (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm, assessed on 1st May 2014)

Paracelsus. Toxipedia (http://www.toxipedia.org/display/toxipedia/Paracelsus, Accessed on 1st September 2014)




About this article

Title

THE CURIOUS CASE OF LOMITAPIDE

Date

01-01-2015

Additional Links

Manuscript Submission

Journal

Asian Journal of Pharmaceutical and Clinical Research
Vol 8 Issue 1 (January-February) 2015 Page: 69

Print ISSN

0974-2441

Online ISSN

2455-3891

Authors & Affiliations

Shariq Naeem Syed
Department of Clinical Pharmacology, Maulana Azad Medical College, New Delhi (INDIA) 110002
India

Vandana Roy
Department of Clinical Pharmacology, Maulana Azad Medical College, New Delhi (INDIA) 110002
India

Piyush Misra
Department of Clinical Pharmacology, Maulana Azad Medical College, New Delhi (INDIA) 110002
India

Akhil Dahiya
Department of Clinical Pharmacology, Maulana Azad Medical College, New Delhi (INDIA) 110002
India


Article Tools


Email this article (Login required)
Email the author (Login required)

Refbacks

  • There are currently no refbacks.